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Abstract 
The Human Immunodeficiency Virus (HIV) subtype C accounts for the majority of infections 
in Southern Africa. The HIV protease is one of the targets in HIV treatment due to its pivotal 
role in HIV maturation in the host cell. However, because of polymorphisms in the HIV 
genome, drug resistance becomes a major problem in HIV treatment. Polymorphisms in the 
HIV protease gene result in altered substrate cavities, and /or flap hinge modifications leading 
to unfavourable drug interaction with the enzyme. The most common form of drug resistant 
mutations is single amino acid substitutions. Although, amino acid insertions have been 
reported, this form of mutation in the HIV protease is rare. L38↑N↑L insertion is a unique 
form of HIV protease polymorphism that was isolated from a patient failing drug therapy in 
South Africa. The objective of this research was to assess the impact of the L38↑N↑L 
insertions, with accompanying background mutations, on the structure and function of this 
form of polymorphism in HIV-1 South African subtype C protease. The far-UV circular 
dichroism (CD) spectra of L38↑N↑L protease shows a trough at 203 nm, suggesting 
alterations in the secondary structure content of this mutant. Whereas the wild type (WTCSA-
HIVPR) displays a trough at 215 nm. However, tertiary structure characterisation using 
fluorescence spectroscopy did not detect changes within the local tryptophan environment of 
L38↑N↑L protease in comparison with the wild type due to no significant shift in emission 
wavelength. The specific activity of L38↑N↑L protease and wild type was 
28.0±1.3 μmol.min-1.mg-1 and 123.45±6.4 μmol.min-1.mg-1 respectively. The turn-over 
number for L38↑N↑L protease and wild type was 1.0 × 10-3 ± 6.0 × 10-5 and 7.7 × 10-3 ± 5.6 
× 10
-4
 respectively. As much as the presence of known drug resistance mutations in L38↑N↑L 
can be attributed to drug resistance, it should also be noted that the insertions may have also 
caused local structural alterations that may have enhance drug resistance of L38↑N↑L. These 
changes could have lead to the decreased catalytic activity of the L38↑N↑L protease. 
Homology modelling studies show that the insertions in L38↑N↑L protease may have 
resulted in a fold similar to 2HS1 (PDB code), which has a modification on the flap hinge. In 
addition, the homology modelling studies suggest that L38↑N↑L protease may have a second 
inhibitor binding site next to one of the flap hinge regions as seen in the 2HS1 model. In 
conclusion, the L38↑N↑L insertions and accompanying background mutations may have 
contributed to the local structural modifications that lead to drug resistance in L38↑N↑L 
protease. 
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CHAPTER 1 
1. Introduction 
 
1.1. HIV/AIDS epidemic 
The Human Immunodeficiency Virus (HIV), the causative agent of acquired 
immunodeficiency syndrome (AIDS) (Weiss et al., 1985; Gallo and Montagnier, 1988) 
remains one of the major causes of death worldwide, particularly in sub-Saharan Africa, with 
an estimated 1.8 million deaths in 2010 (UNAIDS, 2010; WHO, 2011). According to the 
2010 UNAIDS global report, sub-Saharan Africa is home to 68% of the world‟s total 
population living with HIV (UNAIDS, 2010). According to this report, South Africa is one of 
the African countries most affected by the epidemic, with a reported 17 – 18% incidence rate 
(UNAIDS, 2010; SANAC, 2011; WHO, 2011). 
HIV has a high genetic diversity. For this reason, it is classified according to types, groups, 
subtypes and recombinant forms, based on phylogenetic and genetic distance analysis 
(Charneau et al., 1994; Subbarao and Schochetman, 1996; Simon et al., 1998; Roques et al., 
1999; Robertson et al., 2000; Leitner et al., 2005). HIV is divided into two distinct groups, 
HIV-1 and HIV-2. HIV-1 is mainly responsible for the worldwide epidemic, whereas HIV-2 
exists in West Africa (Clavel et al., 1986). It is proposed that HIV-2 is restricted to West 
Africa because it does not spread as easily as HIV-1, and infected individuals acquire 
immunodeficiency slower than those infected with HIV-1 (Reeves and Doms, 2002; Parkin 
and Schapiro, 2004). 
HIV-1 is divided into nine subtypes; A-D, F-H, J and K whereas HIV-2 is divided into groups 
A to G (Gao et al., 1994; Chen et al., 1997; Yamaguchi et al., 2000). In terms of global 
distribution of HIV-1 subtypes, sub-Saharan Africa shows the greatest diversity, with 
subtypes A and C predominating. Subtype A is found in the northern part of sub-Saharan 
Africa and subtype C in southern Africa as shown in Figure 1. Subtype B is the main subtype 
in developed countries such as North America, Western Europe and Australia (Montano et 
al., 1997; Essex, 1999). HIV-1 subtypes can be further divided into sub-subtypes; circulating 
and the unique recombinant forms (Brodine et al., 1995; Fleury et al., 2003; Kantor and 
Katzenstein, 2004). These variant forms differ in phenotype and genotype and are referred to 
as naturally occurring polymorphisms (NOPs) (Coman et al., 2008b). 
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Figure 1 Geographical distribution of HIV-1 subtypes.  
Subtype B is found in North America, Western Europe and Australia. Sub-Saharan Africa 
shows the greatest diversity; with subtype C predominating in the South and East. Subtypes 
A and D are also present, but with lower frequencies. The CRF02_AG and other recombinant 
forms exist in West and West central Africa, although at a low frequency. In central Africa 
there is an array of rare subtypes and recombinant forms with no predominating strain 
(http://www.pbs.org/wgbh/pages/frontline/aids/atlas/clade.html accessed 20 October 2011). 
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One of the biggest challenges with HIV-1 has been the radical emergence and spread of 
HIV -1 C viruses, which are responsible for 50% of global infections (Esparza and 
Bhamarapravati, 2000; Kantor and Katzenstein, 2004; Hemelaar et al., 2006). It is proposed 
that the increase in the number of subtype C infections could be a result of the ease with 
which subtype C viruses are transmitted. The cellular transcription factor, NFkβ, is 
responsible for viral transcription up-regulation (Baeuerle, 1991). Apparently, the presence of 
an extra NFkβ binding site in the long terminal repeat (LTR), found in the subtype C may 
enhance gene expression, which in turn alters transmission and pathogenesis (Tatt et al., 
2001). Another reason could be that subtype C viruses have an enhanced catalytic activity 
compared to other subtypes as shown by the Freire group (Velazquez-Campoy et al., 2001c). 
 
1.2. HIV life-cycle 
HIV infects lymphocytes and macrophages due to the specific interactions it makes with the 
CD4
+
 receptor, when entering these cells (Maddon et al., 1986; Ashorn et al., 1990). An 
outline of the HIV life-cycle is depicted in Figure 2. The virus fuses with the host‟s plasma 
membrane. Once it is taken up by the host, the virus becomes partially uncoated, allowing 
reverse transcription to take place (Farnet and Haseltine, 1991), resulting in production of 
double-stranded DNA from single-stranded RNA. It is suggested that both linear and circular 
DNA are produced from this process, but only the linear DNA is capable of being integrated 
(Brown et al., 1987). The linear viral DNA is transported to the nucleus as part of a protein 
complex involving matrix protein and integrase (Burkrinsky et al., 1992). The integrase 
enzyme facilitates the incorporation of the viral DNA with the host cell DNA. Integration of 
the viral DNA is not site-specific (Ratner, 1993). 
The viral DNA is transcribed along with the host cell DNA. The resulting viral RNAs are 
spliced and moved from the nucleus to the cytoplasm, in order for translation to take place. 
These RNA molecules encode different structural and functional precursor proteins of the 
virus (Nutt et al., 1988). The Gag and Gag-Pol precursor proteins, along with two RNA 
molecules are transported to the plasma membrane where they are assembled, thus forming 
an immature viral particle (Beschiaschvili and Baeuerle, 1991). Viral assembly occurs at the 
plasma membrane of the host cell. The Gag and Gag-Pol products migrate towards the 
membrane and are anchored to the cytoplasmic side by a covalent N-terminal-linked myristic 
acid (Henderson et al., 1983; Mervis et al., 1988).   
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Figure 2 The life cycle of HIV. 
The HIV life-cycle begins with the virus attaching to the host cell via the CD4
+
 receptor. The 
virus then fuses with the membrane becoming partially uncoated, releasing important 
structural and functional components. Reverse transcription of viral RNA takes place. New 
viral DNA is transported to the nucleus where it is integrated with host DNA. After DNA 
transcription, the new viral RNA is transported out of the nucleus where it is transported to 
the plasma membrane along with viral protein. Viral assembly takes place at the plasma 
membrane and an immature virion is formed. The virus then buds of the host cell and is ready 
to infect new cells. Important functional proteins in the HIV life cycle are shown in the red 
boxes (taken from www.HIVwebstudy.org accessed 19 July 2011). 
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Electron micrographs showing the steps involved in viral assembly suggest that the 
polyproteins aggregate, followed by the membrane bulging outward. The nascent viral 
particles then bud from the plasma membrane (Gonda et al., 1985). It is postulated that viral 
particles mature after budding has taken place and  HIV protease may have a role in 
controlling the maturation of the virus. This is based on the fact that dimerisation of the HIV 
protease monomers takes place before proteolysis of the polyproteins (Navia et al., 1989). 
Secondly, the protease assumes a soluble form after cleavage from the Gag-Pol polyprotein. 
Once soluble, the protease diffuses away from the plasma membrane, preventing premature 
initiation of viral maturation. Due to the major role it plays in the life-cycle of HIV, the 
protease is one of the major drug targets in anti-HIV therapy (De Clercq, 2007). 
 
1.3. HIV protease  
HIV protease is a member of the aspartyl protease family on the basis of the conserved Asp-
Thr-Gly active site sequence (Toh et al., 1985). In addition, HIV protease is inhibited by 
pepstatin, which is a common aspartyl protease inhibitor (Hansen et al., 1988; Seelmeier et 
al., 1988; Darke et al., 1989). It is the only member of the aspartyl protease family that is 
dimeric. HIV protease catalyses its release from the viral Gag-Pol precursor through cleavage 
at the amino and carboxyl - terminus (Debouck et al., 1987; Farmerie et al., 1987; Giam and 
Boros, 1988). It is also responsible for release of the poly-protein precursor products (Witte 
and Baltimore, 1978; Crawford and Goff, 1985; Katoh et al., 1985; Farmerie et al., 1987; 
Darke et al., 1988). HIV protease plays an essential role in viral maturation, as shown by 
inactivation through mutagenesis (Asp 25 to Asn, Thr or Ala) or chemical inhibition 
(pepstatin) (Hansen et al., 1988; Kohl et al., 1988; Mous et al., 1988; Seelmeier et al., 1988; 
Darke et al., 1989; McQuade et al., 1990). For this reason, HIV protease is one of the major 
targets in anti-HIV therapy (De Clercq, 2007). 
There are 25 antiretroviral (ARV) drugs approved for the treatment of HIV (Alfonso and 
Monzote, 2011). These drugs include reverse transcriptase inhibitors (nucleotide, nucleoside 
and non-nucleoside inhibitors), integrase inhibitors, HIV cell entry inhibitors (fusion 
inhibitors, and co-receptor antagonists) and protease inhibitors (De Clercq, 2009). These 
inhibitors are used in combination and complement each other in HIV drug therapy (Kantor 
and Katzenstein, 2004; De Clercq, 2009) . 
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1.3.1. Structure of HIV-1 protease 
Protein crystallography is one of the important techniques used in elucidating the structure of 
proteins and HIV protease. Interactions displayed in the X-ray crystal structures of protease 
are exploited for the design of antiretroviral drugs, improving specificity, and the potency of 
protease inhibitors (Kantor and Katzenstein, 2004). HIV protease is an obligate homodimer, 
with each monomer possessing 99 amino acids. The homodimeric protease structure consists 
of nine β strands, and two α helices (Figure 3), and these structural characteristics are 
conserved in all HIV proteases. The two subunits, interact by means of a two-fold axis of 
symmetry (Navia et al., 1989), and are stabilised by anti-parallel interactions between the 
catalytic residues; Asp 25, Thr 26, Gly 27 in one subunit, and Asp 25´, Thr 26´, Gly 27´ in 
the other (Navia et al., 1989). The protease structure has distinct regions namely; the flaps, 
the flap elbow (flap hinge), the active site, and the dimer interface, as shown in Figure 3.  
 
1.3.2. The flap region 
The protease flaps are dynamic moieties that result from the folding of two anti-parallel β 
strands (Miller et al., 1989). The flaps have a high glycine content which allows for 
flexibility of the protease in this region (Lapatto et al., 1989; Navia et al., 1989; Wlodawer et 
al., 1989). The protease flaps play an essential role in the activity of the protease by 
controlling entry of substrate or inhibitor to the active site (Navia et al., 1989). The flaps are 
also involved in substrate recognition (Prabu-Jeyabalan et al., 2006). When the active site is 
free of substrate or inhibitor, the flaps are flexible but still maintain reasonable coverage of 
the active site in an effort to keep the hydrophobic residues buried. This conformation is 
referred to as the “semi-open” form (Hornak et al., 2006b). It has also been, suggested that 
the flaps are rigid and that flexibility is confined to the flap tips, and the flap elbows act as 
hinges (Freedberg et al., 2000; Hornak et al., 2006b). The flap and the flap elbow work as a 
single entity. Therefore, any movements or changes that occur in the elbow region are 
conveyed to the flap tip (Clemente et al., 2004; Perryman et al., 2006; Coman et al., 2008b).  
 
1.3.3. The active site 
The protease active site is a symmetrical cavity that is located below the flaps (Navia et al., 
1989), as viewed in Figure 3. Each protease monomer contributes a conserved amino acid  
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Figure 3 Ribbon representation of HIV-1 subtype C protease with bound Nelfinavir.  
The structure of HIV protease consists mainly of β sheets and has two α helices (shown in 
orange). The flap region is shown in deep purple and consists of residues 44 to 57 from each 
monomer. Flap tips 49-53. Flap movements are controlled by the flap hinge / elbow (shown 
in dark blue) made up of residues 37 to 43. The protease inhibitor Nelfinavir (shown in 
green) is bound to the active site. Each monomer contributes one catalytic Asp 25 residue 
(shown in yellow). The dimer interface (shown in red) lies below the active site is made up of 
the C- and N -termini of each monomer. It is made up of residues 1 to 4; and 69 to 99. This 
Figure was generated using PyMOL with PDB code 2R5Q (DeLano, 2002). 
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sequence known as the catalytic triad (Asp 25 –Thr 26 – Gly 27) to the active site (Navia et 
al., 1989). The two aspartates are in close proximity, in a coplanar orientation, with their 
carboxylate oxygens hydrogen bonded to the amide hydrogens of Gly 27 and Gly 27ʹ. At the 
same time, the two active site threonine residues are hydrogen bonded to main chain amide 
and carboxyl groups from the other chain to form a hydrogen network known as the 
„fireman‟s grip‟(James and Sielecki, 1983). 
 
1.3.4. The dimer interface 
Dimerisation of the two protease monomers is essential for catalysis because both substrate 
binding and the active site require interactions from both monomers (Wlodawer et al., 1989). 
The majority of forces stabilising the dimer interface are formed by the interactions between 
four anti-parallel β strands (residues 1 – 4; and 96 – 99). This region consists of both the N- 
and C-termini of each subunit (Todd et al., 1998). The flap region also has minor interactions 
between residues 48 and 54, from each monomer. Stability studies have shown that the dimer 
interface is important for the stabilisation of the global structure of HIV protease. Upon 
disruption of the interface, the structure collapses into two unstable monomers. This suggests 
that stabilisation of the monomer is not due to intrinsic forces but rather the interaction with 
each other to form the dimer (Todd et al., 1998).  
 
1.4. The catalytic mechanism of HIV-1 protease 
Substrate or inhibitor binding causes the HIV protease flaps to assume a less dynamic 
conformation. The flaps are pulled in towards the bottom of the active site, close to the 
catalytic residues (Hornak et al., 2006b). Hydrogen bonds between side chains also keep the 
flaps in close contact. An important result of flap closure is the exclusion of water, providing 
the protease with a hydrophobic environment essential for catalysis (Velazquez-Campoy et 
al., 2003a). The flaps coordinate a catalytically important water molecule while in the closed 
conformation. This process helps position the substrate for catalysis (Baca and Kent, 1993). 
The peptide bond that is cleaved by HIV protease is termed the “scissile” bond and it is found 
between P1 and P1ʹ according to the Schechter and Berger convention (Schechter and Berger, 
1967), where “P” refers to peptide. The flanking amino acids towards the amino - terminus 
are termed P1, P2, P3, and P4. Similarly, amino acids located towards the carboxyl - terminus 
are named P1ʹ, P2ʹ, P3ʹ, and P4ʹ. The corresponding sub-sites on the protease are named from 
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the central aspartates S1, S2, S3, S4, S1ʹ, S2ʹ, S3ʹ, S4ʹ (Schechter and Berger, 1967). This is 
depicted in Figure 4. 
The two catalytic Asp 25 residues from each monomer have a water molecule between them 
and they exist in opposite states of protonation (Hyland et al., 1991a; Hyland et al., 1991b; 
Ido et al., 1991; Das et al., 2010).The pKa of these aspartates are lower than those existing in 
aqueous environments. Substrate binding increases the pKa from approximately 3.3 to 5.1 
(Ido et al., 1991). The catalytic mechanism of HIV protease, as shown in Figure 5, follows 
general acid-base catalysis. In the free native enzyme, represented as EH
-
 in Figure 5, the 
catalytic aspartates share a proton as well as a water molecule. Since Asp 25 and Asp 25ʹ are 
identical, the negative charge is assigned to the water oxygen. Upon binding of substrate, an 
enzyme-substrate complex (EH
-•S) is formed. The negative charge on the water causes the 
water molecule to conduct a nucleophilic attack on the substrate carbonyl carbon. At the 
same time, the carbonyl oxygen interacts with hydrogen 1 (H1). This leads to the formation of 
an unstable tetrahedral oxyanion intermediate in the transition-state (TS). Collapse of the 
oxyanion intermediate is caused by peptide bond breakage through the transfer of the water 
oxygen, and hydrogen 3 (H3) to the peptide nitrogen to give an enzyme product complex 
(E•P), as shown in Figure 5. Release of products leads to the re-formation of EH- (Ido et al., 
1991; Tomasselli and Heinrikson, 2000; Dunn, 2002). 
 
1.5. Protease inhibitors (PIs) 
The development of HIV PIs is one of the most successful examples of structure-based drug 
design. The three-dimensional structure of HIV protease, interactions of the protease flaps 
with the natural substrate, as well as the catalytic mechanism were central in the structure-
based drug design of PIs. The primary sequence of the natural substrates was also taken into 
account (Wlodawer and Erickson, 1993). The main role of PIs is to prevent the protease from 
cleaving the Gag-Pol polyprotein into essential products. Using an analogy similar to that of 
the lock and key, inhibitor binding acts as a key, „locking‟ the enzyme, thus rendering it 
inactive (Sawant et al., 2008). The resulting immature virions are cleared from the cell by a 
mechanism that is still not well understood. It is important to note that PIs prevent maturation 
of viral particles but cannot influence cells that are already infected. In essence, they act in 
the prevention of the spread of new infections (Robins and Plattner, 1993; Leonard, 1996; 
Sawant et al., 2008).  
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Figure 4 Diagram showing the Schechter and Berger conventional nomenclature.  
The amino acids towards the amino - terminus are named P1, P2, P3, and P4. Similarly, 
substrate amino acids towards the carboxyl - terminus are named P1ʹ, P2ʹ, P3ʹ, and P4ʹ. The 
corresponding sub-sites on the protein are named from the central aspartates S1, S2, S3, S4, 
and S1ʹ, S2ʹ, S3ʹ, S4ʹ. (Adapted from Wlodawer and Vondrasek, 1998) 
 
  
S3 S1 S2ʹ S4ʹ 
S1ʹ S2 S4 S3ʹ 
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Figure 5 A schematic representation of the catalytic mechanism of the HIV protease.  
The Asp residues from each monomer form hydrogen bonds with the conserved water 
molecule. The conserved water molecule becomes activated in order to carry out a 
nucleophilic attack on the carbonyl group of the peptide scissile bond producing an unstable 
tetrahedral substrate that collapses to give hydrolysed products and free enzyme ( Taken from 
Tomasselli and Heinrikson, 2000).  
1 
2 
3 
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2 
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Three generations of PIs have been developed in an effort to improve efficacy, longevity, and 
reduce side effects of infected individuals (Piacenti, 2006). To date there are ten PIs approved 
by the USA, Food and Drug Administration (FDA). These drugs are: Saquinavir, Ritonavir, 
Indinavir, Nelfinavir, Amprenavir, Lopinavir, Fosamprenavir, Atazanavir, Tipranavir and 
Darunavir (De Clercq, 2009). The first five PIs are classified as first generation inhibitors. 
Lopinavir, fosamprenavir and atazanavir are second generation inhibitors. Tipranavir and 
darunavir are third generation drugs. Second and third generation inhibitors, also known as 
the adaptive inhibitors were developed due to the decrease in efficacy of first generation 
drugs. Mutations found within the protease cavity cause changes in geometry of the active 
site, leading to a decrease in the number of hydrogen bonds, van der Waals interactions as 
well as other favourable interactions. Adaptive inhibitors have flexible moieties that allow 
better adaptation to mutations (Todd et al., 2000; Velazquez-Campoy et al., 2001a; Vega et 
al., 2004; Ohtaka and Freire, 2005).  
The interaction between HIV protease and PIs is mainly hydrophobic, which is similar to the 
interaction it has with the natural substrates. Structurally, HIV PIs can be classified as 
peptidomimetic and non-peptidomimetic. A structural characteristic of peptidomimetics is 
that they contain a non-hydrolysable transition-state mimic. The natural cleavage site is 
replaced by a transition-state isostere, such as hydroxyethylene. All the above mentioned PIs 
are peptidomimetics except for tipranavir, which is based on a coumarin scaffold (Navia et 
al., 1989; De Clercq, 2009).  
Dimeric HIV protease is symmetrical, and so the design of most PIs makes use of this 
characteristic. Symmetrical inhibitors exhibit tighter binding, however, they are more prone 
to viral resistance resulting from amino acid changes that affect binding. This is because a 
single amino acid mutation can have a great impact on inhibitor binding (Sawant et al., 
2008). The chemical structures of three PIs that were available in our laboratory while this 
study was conducted are shown in Figure 6. Important structural elements for each inhibitor 
are shown. 
 
1.5.1 Saquinavir 
Saquinavir or Invirase® is a PI designed by Hoffman-La Roche (Basel, Switzerland). It was 
the first PI to undergo clinical trials. It is a pentapeptide analogue. Characteristic features of 
Saquinavir are a hydroxylethylamine transition-state analogue replacing the cleavable scissile 
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bond, a bulky decahydroquinoline in place of proline at position P1ʹ and a quinoline at 
position P3 (Roberts et al., 1990). These structural elements are shown in Figure 6. 
1.5.2 Ritonavir 
Ritonavir or Norvir® was developed by Abbott Laboratories (Illinois, USA). It is derived 
from a C2-symmetric, peptidomimetic inhibitor. It is a hydroxyethyl transition-state isostere. 
It has two thiazole termini, and hydrophobic Phe and Val substituents, increasing its oral 
bioavailability relative to that of Saquinavir (Ho et al., 1994). It is described as a potent 
inhibitor, without killing normal cells, as seen when tested against a variety of laboratory  
strains and clinical isolates (Kuroda et al., 1995). Ritonavir has been shown to inhibit 
cytochrome P450–3A. It is, therefore used to inhibit the rapid metabolism of other protease 
inhibitors such as Saquinavir, delaying the development of resistance (Kempf et al., 1997). 
1.5.3 Nelfinavir  
Nelfinavir or Viracept® was developed by Agouron Pharmaceuticals (La Jolla, USA). It has 
the same bulky hydrophobic group and hydroxyethylamine transition-state isostere as 
Saquinavir, except it has an extended P1 substituent making it a lipophilic inhibitor. 
 
Despite the wide range of clinically used PIs there is still an increase in the number of 
resistance associated infections. This is attributed to a decrease in PI efficacy as a result of 
viral strains with specific amino acid mutations that lower their affinity for inhibitors, while 
maintaining normal function (Velazquez-Campoy et al., 2003a). 
1.6. Mutations 
The emergence of multi-drug resistant HIV strains is caused by a number of reasons. To 
begin with, it is because of the high replication rate of HIV, as well as the low fidelity and 
lack of proof-reading abilities of reverse transcriptase (Roberts et al., 1988; Coffin, 1995). 
Drug pressure, poor patient compliance to ARV treatment and cross infection between 
patients also gives rise to new viral strains which encode mutated reverse transcriptase and 
protease enzymes (Richman et al., 1994; Coffin, 1995; Ho et al., 1995; Robertson et al., 
1995a; Robertson et al., 1995b; Wei et al., 1995). 
There are specific mutations (single or group point mutations, which are essentially amino  
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Figure 6 The chemical structures of three FDA approved protease inhibitors. 
PIs are generally bulky and highly hydrophobic. The PIs shown above are first generation 
inhibitors. A common characteristic is that they are peptidomimetics.   
Phe 
Phe 
Thiazole 
group 
Thiazole 
group 
Val 
hydroxylethylamine transition state 
analogue 
Quinoline 
decahydroquinoline 
hydroxylethylamine 
transition state analogue 
decahydroquinoline 
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acid substitutions) that occur in response to specific drugs. For example, Saquinavir 
resistance is due to G48V and I84V; Indinavir and Ritonavir V82A/T/F/S and I84V; 
Nelfinavir by D30N and I84V (Velazquez-Campoy et al., 2003a). Drug resistance mutations 
are classified as either primary or secondary mutations. Most primary mutations are found 
within the substrate binding pocket. They are conservative mutations (charge and polarity are 
conserved) but the geometry is altered. Primary mutations directly reduce drug binding, and 
in some cases even the binding of the natural substrate, thus affecting viral replication. 
Secondary mutations rectify this problem by playing a compensatory role. They improve 
proteolytic efficiency and increase viral replication (Boom et al., 1990; Nijhuis et al., 1999; 
Shafer, 2002). In addition to primary and secondary mutations within the protease, amino 
acid changes are also introduced in the cleavage sites of viral Gag and Gag-Pol polyproteins 
so that the mutated protease is able to bind and catalyse these polyproteins (Doyon et al., 
1996; Zhang et al., 1997; Mammano et al., 1998) 
The type and location of an amino acid polymorphism is confined by the need for the enzyme 
to maintain catalytic function. Mutations are normally found in the flap hinge region, in the 
loop connecting the β strands and the α-helix and opposite β strand (Velazquez-Campoy et 
al., 2003b). The hinge region and the α-helix play an important role in flap dynamics and 
subunit rotation. Mutations in these regions affects inhibitor binding (Velazquez-Campoy et 
al., 2001c). 
Another aspect of decreased drug efficacy involves NOPs. Some amino acids that occur 
naturally in non-subtype B are associated with drug resistance in subtype B protease, 
questioning the efficiency of PIs in non-subtype B proteases. For example the M36I mutation 
in subtype B exists as a drug resistant mutation, but in subtype C, Ile 36 occurs naturally 
(Becker-Pergola et al., 2000). NOPs, in the absence of drug pressure, are found in areas that 
do not lead to loss of structural stability or .loss of catalytic activity (Velazquez-Campoy et 
al., 2003b). 
 
1.6.1. Insertions 
During ARV therapy insertions, instead of mutations are sometimes selected. In isolates from 
patients failing drug therapy, insertions in both reverse transcriptase and protease are 
sometimes found (Masquelier et al., 2001; Winters and Merigan, 2005). It is suggested that 
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most insertions are duplicates of neighbouring DNA sequences. This may be a result of 
primer or template slippage during the reverse transcription process (Kozisek et al., 2008). 
Insertions in the HIV protease gene are fairly rare with a prevalence rate of 0.1% (Kim et al., 
2001). According to a mutation survey conducted by the Konvalinka group (Kozisek et al., 
2008), most insertions occur between residues 32 and 41. This includes the substrate cleft and 
the flap hinge. Insertions occur in regions of the protease that are next to externally exposed 
loops. The reason could be that these regions may be able to accommodate the extra amino 
acids by extending outwards, thus, preventing tremendous changes in the overall structure of 
the protein (Winters and Merigan, 2005).  
The susceptibility of PIs to insertions is dependent on whether they occur in the presence of 
major protease resistance mutations. It was found that insertions that occurred in the absence 
of major drug resistant mutations were completely susceptible to PIs. Insertions that occurred 
in addition to drug resistant mutations showed a reduced susceptibility to PIs (Kim et al., 
2001; Sturmer et al., 2003). Although the prevalence rate of insertions is low, there seems to 
be a slow increase since 1999 (Kozisek et al., 2008). Insertions are transmittable between 
individuals and could lead to the spread of new forms of drug resistant strains (Winters and 
Merigan, 2005). 
The first insertion to be reported was M36T↑N↑L, found in a drug naïve patient infected with 
subtype B (Sturmer et al., 2003). It is a six base-pair insertion at position 36. The M36T↑N↑L 
insertion did not show any drug susceptibility because it does not occur in the presence of 
drug resistant mutations. Position 36 in HIV protease is prone to alterations either as point 
mutations or insertions; M36I is a drug resistant mutation found in subtype B (Sturmer et al., 
2003). Other examples of insertions include L33↑L and E35↑E. The E35↑E mutant 
contributes towards PI resistance by increasing protease vitality in the presence of inhibitors 
such as Saquinavir, Ritonavir and Lopinavir. Vitality in the presence of Nelfinavir is, 
however, decreased (Kozisek et al., 2008). The L33↑L insertion increases protease vitality in 
the presence of all the above mentioned inhibitors, including Nelfinavir. HIV protease 
binding affinity for Nelfinavir is decreased by a factor of ten as a result of the L33↑L 
insertion (Kozisek et al., 2008). 
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1.6.2. L38↑N↑L protease 
Sequencing of the blood samples of a drug-treated patient infected with HIV-1 South African 
subtype C revealed a unique protease, L38↑N↑L, with two insertions. This patient was 
reportedly failing drug therapy. The protein sequence of L38↑N↑L is shown in Figure 7 A, 
which shows the position of Leucine 38, and the amino acid mutations (E35D, I36G, N37S, 
M46L, D60E) that accompany the insertions. According to the Stanford database 
(http://hivdb.stanford.edu/cgi-bin/), E35D, N37S, M46L and D60E have all been identified as 
drug resistance mutations. Figure 7 B is the sequence alignment of L38↑N↑L protease with 
South African subtype C protease. The Q7K mutation in South African subtype C as shown 
in the alignment was introduced to minimise auto-proteolysis (Mildner et al., 1994). In the 
context of this study  
 
1.7. Objective 
The L38↑N↑L HIV subtype C protease sequenced from a patient failing drug therapy selected 
two amino acid insertions, along with drug resistance mutations. The specifics as to which 
drug regimen the patient was on, was not of importance in the context of this study. It was 
however, important to study this unique protease that has a hundred and one amino acids 
compared to the expected ninety nine amino acids. The main objective of this study was 
therefore to assess the impact these insertions have on the structure and function of South 
African subtype C protease.  
To achieve this objective, this study aims to: 
1. Construct L38↑N↑L protease and associated mutations (E35D, I36G, N37S, M46L and 
D60E) using polymerase chain reaction (PCR) and mutagenesis.  
2. Optimise the expression of the L38↑N↑L protease. This is achieved by performing 
induction studies. 
3. Purify recombinant wild type (WTCSA-HIVPR) and L38↑N↑L protease using anion 
exchange chromatography. 
4. Analyse and compare the secondary and tertiary structure of both wild type (WTCSA-
HIVPR) and L38↑N↑L protease. 
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5. Obtain protease enzyme kinetic parameters in order to assess the enzyme activity of the 
L38↑N↑L protease in comparison to the WTCSA-HIVPR. 
6. Use homology modelling to predict the structure of L38↑N↑L protease.  
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C-SA   PQITLWKRPLVSIKVGGQIKEALLDTGADDTVLEEINL--PGKWKPKMIGGIGGFIKVRQ 
       ::::::.:::::::::::::::::::::::::::...:  :::::::.:::::::::::: 
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Figure 7 A) HIV-1 South African subtype C protease B) Sequence alignment  
A) ribbon representation of HIV-1 South African subtype C protease. The location Leu 38 is 
represented with the green sphere. The position of the accompanying point mutations are 
represented with the red spheres. This Figure was generated using PyMOL (PDB code 3U71) 
(DeLano, 2002).  B) A sequence alignment of South African subtype C WTCSA-HIVPR 
(Mosebi et al., 2008) (A) with L38↑N↑L protease (B). The amino acid residues highlighted in 
red are the amino acid point mutations, and the ones highlighted in blue are the insertions.  
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CHAPTER 2 
2. Materials and methods 
 
2.1. Materials 
The pET-HIVPR expression vector contains a gene encoding HIV protease subtype B. The 
vector was a kind gift from Dr J. Tang, (Health Science Centre, University of Oklahoma, 
Oklahoma city, United States of America) (Ido et al., 1991). Site directed mutagenesis was 
used to convert subtype B protease to South African subtype C protease (WTCSA-HIVPR) 
by Dr S. Mosebi, (Protein Structure-Function Research Unit, University of the 
Witwatersrand, Johannesburg, South Africa) (Mosebi et al., 2008). A Q7K point mutation 
was introduced in order to minimise autocatalysis (Mildner et al., 1994). Molecular grade 
urea used was purchased from Merck (Darmstadt, Germany). A GeneJet
TM
 plasmid and 
purification kit purchased from Fermentas (Vilnius, Lethuania). Stratagene QuikChange® 
Lightning Site-Directed Mutagenesis Kit was purchased from Stratagene (Illinois, USA.), and 
the mutagenesis oligonucleotide primers from Inqaba Biotec
TM
 (Pretoria, South Africa).The 
chromogenic substrate was a kind gift from Dr. T. Govender, (School of Pharmacology, 
University of KwaZulu-Natal). Protease inhibitors Saquinavir, Nelfinavir and Ritonavir were 
a kind gift from the National Institute of Allergy and Infectious Diseases (NIH AIDS 
Research and Reference reagents program, Germantown, United States of America). Other 
reagents were of analytical grade. 
 
2.2. Source of HIV protease sequence  
HIV-1 protease sequence data from a South African patient infected with South African 
subtype C was provided by Prof. Lynn Morris from the National Institute for Communicable 
Diseases, South-Africa (NICD, Johannesburg, South Africa). This information was used to 
design oligonucleotide primers required for the generation of the L38↑N↑L protease, 
including the following with background mutations: E35D, I36G, N37S, M46L and D60E. 
 
2.3. Primer design and site-directed mutagenesis  
Oligonucleotide primers were designed based on the sequence obtained from the NICD. 
Firstly, when designing the primers, it was important to ensure that the codon which was 
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selected coded for a particular amino acid, is found in both Escherichia coli (E. coli) and 
Homo sapiens. This was done using graphic codon usage analyser (http://gcua.schoedl.de/). 
After designing the primers, the oligonucleotide sequences were uploaded into Oligocalc
TM 
(http://www.basic.northwestern.edu/biotools/oligocalc.html), an online software tool that 
calculates the melting temperatures of the primers. The ideal melting temperature is ≥ 78 °C. 
A reverse complement of the sequences was generated using an online software tool that 
generates the reverse complement of the oligonucleotide primers 
(http://www.bioinformatics.org/sms/rev_comp.html). Table 1 shows sequences of all the 
primers that were used to generate the L38↑N↑L protease. The Stratagene QuikChange® 
Lightning Site-Directed Mutagenesis Kit was used to generate the L38↑N↑L protease along 
with the following background mutations: E35D, I36G, N37S, M46L and D60E. For 
mutagenesis and the polymerase chain reaction (PCR) 20 ng of double stranded DNA and 
125 ng plasmid DNA were used. Other solutions were added according to the manufacturer‟s 
instructions. The PCR cycle parameters that were used are summarised in Table 2. After 
completion of PCR, 1 µL of DpnI restriction enzyme was to digest the parent plasmid 
according to the manufacturer‟s instructions. 
After PCR it was important to propagate the mutated DNA, this was done by transforming E. 
cloni® 10G competent cells (Lucigen, Middleton, USA) with 10 ng of pET-HIVPRL38 from 
the PCR reaction mix and incubated on ice for 30 minutes. The plasmid DNA reaction mix 
was heat shocked at 42 °C for 45 seconds and immediately cooled on ice for 2 minutes. This 
was followed by the addition of 900 mL of SOC medium (super optimal broth supplemented 
with glucose) ( 2% tryptone (w/v), 0.5% yeast extract (w/v), 10 mM sodium chloride, 2.5 
mM potassium chloride and distilled water). The mixture was incubated at 37 °C for 1 hour 
after which 200 µL was plated onto Lysogeny Broth (LB) plates (1 g tryptone, 0.5 g of yeast 
and sodium chloride, 1.5 g agar in 100 mL of distilled water) with 100 μg/mL of ampicillin 
and grown overnight. A single colony was selected and grown in 10 mL of LB media (1g 
tryptone, 0.5 g of yeast and sodium chloride, 1.5 g agar in 100 mL of distilled water). A 
GeneJet
TM
 plasmid and purification kit (Fermentas) was used to isolate the plasmid from the 
E. cloni® cells. The pET-HIVPRL38 sample containing 10 µg of plasmid was sent to Inqaba 
Biotec
TM
, for sequencing. Inqaba Biotec
TM
 sent results in the form of a chromatogram that 
was viewed using Finch TV. 
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Table 1: Primer sequences used to generate L38↑N↑L protease and the background mutations (E35D, I36G, N37S, M46L and D60E). 
The nucleotides representing the substitution mutations are in red, and the insertion mutations are in blue. 
 
Mutation Primer Sequence 
E35D, N37S Forward 
Reverse 
5ʹ- GAC GAC ACT GTT CTG GAA GAT ATC AGC CTG CCG GGT AAA TGG AAG -3ʹ 
5ʹ- CTT CCA TTT ACC CGG CAG GCT GAT ATC TTC CAG AAC AGT GTC GTC -3ʹ 
I36G Forward 
Reverse 
5ʹ- GAC GAC ACT GTT CTG GAA GAT GGT AGC CTG CCG GGT AAA TGG AAG -3ʹ 
5ʹ- CTT CCA TTT ACC CGG CAG GCT ACC ATC TTC CAG AAC AGT GTC GTC -3ʹ 
N insert  
 
Forward 
Reverse 
5'- GTT CTG GAA GAT GGT AGC CTG AAC CCG GGT AAA TGG AAG CCG AAA CTG ATC GGT G -3' 
5ʹ- CAC CGA TCA GTT TCG GCT TCC ATT TAC CCG GGT TCA GGC TAC CAT CTT CCA GAA C - 3' 
N and L insert  
 
Forward 
Reverse 
5'- GTT CTG GAA GAT GGT AGC CTG AAC CTG CCG GGT AAA TGG AAG CCG AAA CTG ATC G -3' 
5'- CGA TCA GTT TCG GCT TCC ATT TAC CCG GCA GGT TCA GGC TAC CAT CTT CCA GAA C -3' 
M46L 
 
Forward 
Reverse 
5ʹ- GGG TAA ATG GAA GCC GAA ACT GAT CGG TGG CAT CGG CGG -3ʹ 
5ʹ- CCG CCG ATG CCA CCG ATC AGT TTC GGC TTC CAT TTA CCC -3ʹ 
D60E Forward 
Reverse 
5ʹ- ATC AAA GTT CGT CAG TAT GAA CAG ATC CTG ATC GAA ATC TG -3ʹ 
5ʹ- CAG ATT TCG ATC AGG ATC TGT TCA TAC TGA CGA ACT TTG AT -3ʹ 
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Table 2: PCR cycling parameters 
 
Segment Cycles Temperature (°C) Time 
1 1 95 2 minutes 
2 18 95 20 seconds 
60 10 seconds 
68 3 minutes 
3 1 68 5 minutes 
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2.4. Recombinant expression of WTCSA-HIVPR and L38↑N↑L protease in E. 
coli 
HIV-1 protease WTCSA-HIVPR and L38↑N↑L protease were expressed as inclusion bodies 
(Ido et al., 1991) in BL21 (DE3) pLysS cells. These competent cells were transformed with 
the pET-HIVPRC for WTCSA-HIVPR and pET-HIVPRL38 plasmid for L38↑N↑L protease 
Expression conditions for WTCSA-HIVPR required 0.4 mM of isopropyl β-D thiogalactoside 
(IPTG) with 4 hours of induction. Induction studies were carried out in order to determine 
optimal conditions for E. coli expression of the L38↑N↑L protease. The concentration of 
IPTG and times of over-expression were varied. There were six flasks in total (0 mM, 
0.2 mM, 0.4 mM, 0.6 mM, 0.8 mM and 1 mM IPTG). An overnight culture was prepared by 
growing the E. coli BL21 (DE3) pLysS cells harbouring the pET-HIVPRL38 plasmid in fresh 
LB medium at 37 °C in the presence of 100 μg/mL ampicillin and 35 μg/mL 
chloramphenicol. Fresh LB medium (100 mL) was inoculated with the overnight culture 
making a 100-fold dilution and the cells were allowed to grow at 37 °C at 180 rpm until the 
OD600 had reached 0.4 - 0.5. A sample which represented 0 M IPTG, after zero hours of 
induction, was collected. The other five flasks were induced with 0.2 mM, 0.4 mM, 0.6 mM, 
0.8 mM and 1 mM IPTG. The cells in the six flasks were induced for a total of six hours and 
1.5 mL of samples was collected from each flask every hour. The collected samples were 
centrifuged, (16 000 g, 20 minutes, 10 °C) and the pellet resolved on tricine sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) to determine optimal conditions 
for over-expression. The reason the pellet and not the supernatant was analysed is because the 
protease is expressed as inclusion bodies.  
The optimal conditions for WTCSA-HIVPR and L38↑N↑L protease expression were 0.4 mM 
IPTG (at OD600 of approximately 0.4), 4 hours induction at 37 °C in 5 L Erlenmeyer flask 
(shaking at 250 rpm). After four hours of induction, the cells were harvested by 
centrifugation (2700 g, 12 minutes, 10 °C). The cell pellet was re-suspended with ice-cold 50 
mL of Buffer A (10 mM Tris, 2 mM EDTA and 1 mM PMSF pH 8.0) and stored at - 20 °C. 
2.5. Purification and refolding of HIV-1 protease 
Purification of HIV-1 protease was performed using modifications of the method previously 
described by (Velazquez-Campoy et al., 2001c). The cells (stored at - 20 °C) were thawed at 
4 °C and additional buffer A was added to a final volume of 100 mL. Magnesium chloride 
(MgCl2) and DNAse I were added to a final concentration of 10 mM and 10 U/μL, 
respectively. Once the viscosity of the mixture had decreased, the suspension was poured into 
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sterile tubes and sonicated. The sonicated suspension was centrifuged (25000    g, 
30 minutes, 8 °C). The pellet was re-suspended in Buffer A containing 1% (v/v) Triton X-100 
and centrifuged (25000    g, 30 minutes, 8 °C). The pellet was then re-suspended in Buffer B 
(10 mM Tris, 10 mM dithiothrietol and 8 M urea pH 8). The homogenate was centrifuged 
(32500    g, 30 minutes, 20 °C). The supernatant was loaded onto a DEAE anion exchange 
column pre-equilibrated with buffer B. Bradford‟s assay reagent (Bio-Rad, California, USA) 
was used to determine which of the eluted fractions contained protein. The protein-containing 
fractions were pooled and 25 mM formic acid was added, reducing the pH to approximately 
3.0. This results in precipitation of any non-aspartyl protein contaminants. 
The protein was refolded by extensive dialysis against 10 mM formic acid at 4 °C, and then 
against (10 mM sodium acetate buffer, pH 5.0, containing 2 mM NaCl and 2 mM DTT). The 
dialysis buffers were hundred times the volume of the sample. The refolded protein was 
concentrated using ultra-filtration under nitrogen gas. Purity of the L38↑N↑L protease and 
WTCSA-HIVPR protease was assessed using tricine SDS-PAGE. 
 
2.6. Assessment of protein purity using SDS-PAGE  
SDS-PAGE is a technique that separates proteins according to molecular weight. Based on 
how far protein samples travel and how many bands appear, the size and purity can be 
analysed (Laemmli, 1970). SDS is a negatively charged detergent. SDS binds to proteins by 
the same amount and causes proteins to acquire a rod-like shape, with an overall negative 
charge (Reynolds and Tanford, 1970).  
The Laemmli SDS-PAGE method is a discontinuous gel system consisting of a stacking and 
a separating gel. Each gel has a different percentage of acrylamide (Laemmli, 1970). The 
stacking gel stacks the protein sample into a thin band. This is an important step that ensures 
efficient separation of protein samples that have entered the separating gel. If a situation 
arises whereby the proteins are not separated from bulk SDS, streaking of the separated 
protein bands occurs (Schagger and von Jagow, 1987; Schagger, 2006). 
The Laemmli method provides good resolution for proteins above 100 kDa, but ineffectively 
resolves proteins below 30 kDa, and these protein bands appear as smears near the gel front 
(Schagger, 2006). The main reason for this is because SDS-protein complexes of proteins 
below 30 kDa have approximately the same size and charge and therefore cannot be 
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distinguished from each other (Fish et al., 1970). It is, therefore, difficult to separate these 
proteins from bulk SDS. This separation of protein from bulk SDS is important for efficient 
separation to take place within the separating gel (Schagger and von Jagow, 1987). Tricine 
SDS-PAGE was used in this study because it provides better resolution of proteins below 
30 kDa. 
A difference in the degree of separation between the Laemmli and Tricine SDS method relies 
on differences with the trailing ions used, in particular their pKa values. The conventional 
Laemmli method uses glycine as a trailing ion, which has a pKa value of 9.6. Tricine SDS-
PAGE uses tricine, with a pKa value of 8.15. The pKa value affects the electrophoretic 
mobility of the trailing ions with respect to the electrophoretic mobility of proteins (Schagger 
and von Jagow, 1987; Schagger, 2006). Glycine is able to stack large proteins within the 
stacking gel because it migrates slowly within the acidic medium of a stacking gel, therefore, 
increasing the stacking limit. Tricine on the other hand, lowers the stacking limit by moving 
much faster within the stacking gel, relative to the electrophorectic mobility of the protein. 
This is because tricine exists in its anionic form, allowing for faster migration. By decreasing 
the stacking limit, proteins of lower molecular mass are separated efficiently (Schagger and 
von Jagow, 1987; Schagger, 2006). 
Expression and purity of WTCSA-HIVPR and L38↑N↑L protease protein were assessed 
using Tricine SDS-PAGE. Buffers and solutions were prepared as shown in Table 3 
(Schagger, 2006). Figure 8 summaries preparation procedures for Tricine SDS-PAGE 
samples. The protein samples were diluted one two times with sample buffer (10% (w/v) 
SDS, 10% beta mercaptoethanol, 10% (v/v) glycerol and bromophenol blue). The samples 
were incubated at 37 °C for 15 minutes. These samples, along with the protein molecular 
weight marker (Fermentas SM0431) were loaded onto a tricine gel (4% stacking and 16% 
separating). In order to ensure that accuracy of SDS-PAGE results, the same amount of 
sample was loaded on to the tricine gel. The initial voltage used was 30 V until the samples 
reached the separating gel. The voltage was then increased to 130 V.  
2.7. Determination of protein concentration 
The concentrations of WTCSA-HIVPR and L38↑N↑L protease were determined 
spectrophotometrically at 280 nm, using the Beer-Lambert law:  
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Table 3: Preparation of tricine gels.  
 4% sample gel 16% gel 
AB-3* (μL) 1 10 
Gel buffer** (μL) 3 10 
Glycerol (g) - 3 
Add water to a final volume (μL) 12 30 
APS (10%) (μL) 90 100 
TEMED (μL) 9 10 
 
 
*AB3 [48 g acrylamide, 1.5 g bisacrylamide, 100 mL distilled water] 
** Gel buffer (3 M Tris, 1 M HCl, 0.3% (w/v) SDS, pH 8.45) 
Anode buffer  10 stock solution [1 M Tris, 0.225 M HCl, pH 8.9] 
Cathode buffer  10 stock solution [1 M Tris, 1 M Tricine, 1% (w/v) SDS, pH 8.25] 
Fixing solution [50% methanol (v/v), 10% acetic acid (v/v), 100 mM ammonium acetate] 
Staining solution [0.025% Coomassie dye (w/v) in 10% acetic acid (v/v)] 
Destaining solution [10% acetic acid (v/v) solution] 
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Figure 8 Flow diagram showing the steps involved when resolving protein samples on tricine SDS-PAGE. 
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                                                                       A   εcl                                                 Equation 1 
where A is the absorbance of the sample at wavelength λ280 (nm), ε is the molar extinction 
coefficient (M
-1
 cm
-1) at wavelength λ280, c is the molar concentration of the absorbing 
solution and l (cm) is the path length of light passing through the solution. The value of the 
extinction coefficient used was 11800 M
-1
 cm
-1
 (Polgár et al., 1994). 
The protein concentration was determined by diluting the protein sample with 10 mM sodium 
acetate buffer, to make a four times dilution. The absorbance reading was taken at λ280 and 
λ340. The protein was diluted progressively until a ten time‟s dilution was obtained, and the 
absorbance read after each dilution. The 10 mM sodium acetate buffer was used as the blank. 
The λ340 for each dilution was subtracted from the 280 nm absorbance for each dilution. This 
value was then corrected for the buffer. A plot of protein fraction against absorbance was 
plotted. The slope was divided by the extinction coefficient to obtain the protein 
concentration. 
2.8. Protein structure characterisation 
2.8.1. Far-UV Circular Dichroism  
A circular dichroism (CD) spectrum results from the interaction of a chromophore in an 
optically asymmetrical environment with circularly polarised light. In proteins, the backbone 
amide bonds and aromatic amino acids are the main chromophores. In far-UV (250-190 nm) 
CD, the main chromophore is the peptide backbone (Adler et al., 1973; Greenfield, 1996). 
When the peptide backbone has ordered and regular turns, as is the case in alpha helices, beta 
turns and beta sheets, it interacts with circularly polarised light in a specific way to give a 
characteristic CD spectrum (Adler et al., 1972). A single CD spectrum is the sum of the 
spectra of all the conformational elements of that protein. It therefore  provides an estimate of 
the secondary structure (Greenfield, 1999). Proteins with a high alpha helical content exhibit 
two negative bands at 222 nm and 210-208 nm, and a positive band at 190 nm (Venyaminov 
and Yang, 1991; Greenfield, 1996). Alternatively, if a protein is composed predominantly of 
β sheets, a single negative band is obtained between 216 and 218 nm and a positive band at 
190 nm (Venyaminov and Yang, 1991; Greenfield, 1996). Disordered proteins have very low 
ellipticity above 210 nm and a negative band near 195 nm (Venyaminov et al., 1993). HIV 
protease has a high content of β-sheets and has two α helices. The expected CD spectrum 
will, therefore, have one negative band between 216 and 218 nm and a positive band at 
190 nm. 
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Far-UV CD spectra for WTCSA-HIVPR and L38↑N↑L protease were obtained using a Jasco 
J-810 spectropolarimeter. The spectropolarimeter parameters were set at a data pitch of 
0.1 nm and 0.5 nm bandwidth. A 2 mm path length cuvette was used. Since far-UV CD is 
sensitive to chloride ions, protein stocks used for CD studies were diluted to a final 
concentration of 20 μM using sodium acetate buffer pH 5.0 without sodium chloride. Studies 
were carried out at 20 °C.  
The raw CD data was converted to mean residue ellipticity using the following equation: 
 
                                                                  
     
   
                                           Equation 2 
 
Where   is the raw signal (mdeg), c the protein concentration (mM) used, n the number of 
amino acid residues (WTCSA-HIVPR has a total of 198 and L38↑N↑L protease 202 residues) 
and l path length (cm) of light that passes through the cuvette (Woody, 1995).  
 
 2.8.2. Fluorescence spectroscopy 
Fluorescence is the emission of light that results from the electronically excited states to the 
ground state (Lakowicz, 2006). The main fluorophores are the aromatic amino acids, tyrosine 
and tryptophan, with little contribution from phenylalanine. These aromatic residues have 
conjugated double bonds which can be excited with light of a specific wavelength to a higher 
excited electronic state. Once excited, the molecules undergo rapid energy loss through 
internal conversions. The electrons return to the lowest vibrational state of the excited 
electronic state and then the ground state emitting a photon of lower energy. Energy absorbed 
by phenylalanine and tyrosine is often transferred to tryptophan within the same protein. 
Conversely, tryptophan can be quenched by nearby residues within the same protein 
(Lakowicz, 2006). Intrinsic fluorescence is highly dependent on the indole ring of the 
tryptophan residue. The emission spectrum of the indole ring is highly sensitive to solvent 
polarity. The spectrum may be blue-shifted (lower wavelength) when the indole ring is 
buried, and red-shifted (higher energy) when it is unfolded or solvent exposed. The indole 
ring absorbs light energy at 280 nm and emits at a wavelength of approximately 340 nm. 
Therefore, the emission wavelength is indicative of whether tryptophan is buried, or solvent   
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Figure 9 Three dimensional structure of HIV protease showing the position of 
tryptophan and tyrosine residues 
The positions of the fluorescent probes found in HIV protease are shown. Trp 42 is found in 
the flap elbow, whereas Trp 6 is found close to the dimer interface. The magenta spheres 
represent water molecules that are within 4 Å of each tryptophan. Trp 42 is partially buried, 
whereas Trp 6 is highly solvent exposed. This figure was generated using PyMOL (PDB code 
2R8N) (DeLano, 2002). 
Trp 42 
Trp 6 
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exposed (Lakowicz, 2006). For tryptophan residues that are solvent exposed, an emission 
maximum is expected around 350 nm. The emission maximum occurs at a higher wavelength 
(relative to buried tryptophan residues) because when tryptophan residues are solvent 
exposed, the tryptophan indole group involved in hydrogen bonding, decreasing the energy 
(Lakowicz, 2006). Fluorecence spectroscopy was used to characterise the environment of the 
four tryptophan residues in HIV protease. The fluorescent probes in dimeric HIV protease 
are: Trp 6, Trp 6ʹ, Trp 42, Trp 42ʹ Tyr 59 and Tyr 59ʹ. Figure 9 shows the interaction of the 
four tryptophan residues with solvent. 
Fluorescence spectroscopy is a highly sensitive technique which is why a low protein 
concentration is used. The fluorescence spectra for WTCSA-HIVPR and L38↑N↑L protease 
were obtained using a Jasco FP-6300 spectrofluorometer. Fluorescence emission was 
observed between 280 and 500 nm. The excitation and emission slit widths were set at 
0.5 nm. A total of three accumulated scans were averaged to obtain a single spectrum. 
Fluorescence assays were performed using 3 μM of protein in sodium acetate buffer pH 5.0. 
Studies were carried out at 20 °C.  
 
2.9. Enzyme kinetics 
Initial rates are important in understanding the chemical mechanism of an enzyme. When 
performing enzyme kinetic studies it is important to ensure that reactions occur at initial 
velocity. This is because at initial velocity the concentration of reactants is known from the 
amounts added. Secondly, at time zero, there are no products present so there will be no back 
reactions taking place. This ensures that the formation of product is limited by available 
enzyme, and not because of back reactions. In addition, initial velocity studies guarantee that 
no errors occur due to loss of enzyme activity over time (Palmer, 1995b; Michaelis et al., 
2011). At significantly high substrate concentrations, the enzyme becomes saturated, forcing 
the enzyme and substrate to form an enzyme-substrate complex. This ensures that there is no 
unbound enzyme; therefore, the total amount of enzyme in the reaction will be the 
concentration of the enzyme-substrate complex. This follows zero order kinetics, since the 
rate of reaction cannot be increased by increasing the amount of substrate(Michaelis et al., 
2011). 
For a single substrate reaction, the substrate binds the enzyme at a specific binding site, 
forming a relatively stable enzyme-substrate complex. Stability is ensured by placing the 
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reacting groups in close proximity to each other, and the catalytic site of the enzyme. 
Catalysis may involve a second transition-state that quickly collapses to give products. 
Products may still be bound, producing another unstable enzyme-product complex. The rate-
limiting step is the conversion of the enzyme-substrate complex to enzyme-product complex. 
The reaction rate is through determination of maximum reaction velocity (Vmax). This can be 
determined using equation 3 (Palmer, 1995b): 
 
                                                                                                                      Equation 3 
Where [E]0 is the total amount of enzyme present, free enzyme and the enzyme-substrate 
complex. 
According to Michaelis and Menten, equilibrium is established between enzyme, substrate 
and enzyme-substrate complex. The breakdown of the enzyme-substrate complex is too slow 
to disturb the equilibrium, so it is excluded. They depicted the relationship between initial 
velocity and substrate concentration to be the following(Michaelis et al., 2011): 
 
                                                   
        
       
                                                     Equation 4 
 
Where Vmax is the maximum velocity,      is the initial velocity and KM is the substrate 
concentration half Vmax. It is further assumed that the substrate is usually present in much 
higher concentrations than the enzyme. In situations where the substrate concentration is 
assumed to be „low‟, in order to give first order kinetics with a small degree of saturation, the 
substrate concentration may still be a thousand times higher than concentration of enzyme. 
So, if the initial substrate concentration      is much greater than the initial enzyme 
concentration     , then the formation of the enzyme-substrate complex will result in an 
insignificant change in free substrate concentration. Therefore,      can be substituted for [S] 
(Michaelis et al., 2011). 
The Michaelis-Menten equation cannot, however, be applicable to all enzyme catalysed 
systems as some reactions proceed so fast that such an equilibrium is not established. The 
Briggs-Haldan modification states that the steady-state assumption is more valid. The Briggs-
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Haldan claim states that since the concentration of enzyme relative to that of substrate is 
negligible, it also means that the rate of change for the enzyme-substrate concentration will 
also be negligible, compared to that of product [P] over time (Briggs and Haldane, 1925). 
 
2.9.1. Specific activity 
Enzyme activity can be described in terms of the enzyme unit (U), which is the amount of 
enzyme that will catalyse the formation of product from substrate (Wharton and Eisenthal, 
1981). Specific activity is an effective way of expressing enzyme purity and it is referred to 
as the activity of an enzyme per unit weight (U/mg) (Dixon and Webb, 1958; Wharton and 
Eisenthal, 1981). The chromogenic peptide substrate, Lys-Ala-Val-Nle-p-nitro-Phe-Glu-Ala-
Nle-NH2, which mimics the conserved KARVL/AEAM cleavage site between the capsid 
protein and nucleocapsid (CA-p2) within the Gag polyprotein precursor, was used. The 
hydrolysis of this substrate was monitored at 300 nm, using a Jasco V-630 
spectrophotometer. The extinction coefficient used was 1800M
-1 
cm
-1
 (Velazquez-Campoy et 
al., 2001c). The reaction mixture contained 50 μM substrate, protein (within range of 100 -
200 nM) and 50 mM sodium acetate buffer, (pH 5, with 0.1 M sodium chloride), at a final 
volume of 120 μL. 
 
2.9.2. Kinetic parameters 
Catalytic parameters are useful in elucidating the catalytic mechanism. The catalytic 
parameters that were determined for WTCSA-HIVPR and L38↑N↑L protease are the 
Michaelis constant (KM), the turnover number (kcat), the catalytic efficiency (kcat/KM) and the 
maximum velocity (Vmax). The KM is defined in molarity (M). A low KM value indicates high 
substrate binding affinity (Wharton and Eisenthal, 1981). The enzyme turn-over describes the 
number of substrate molecules transformed into product for every enzyme molecule, per unit 
time (s
-1
). The catalytic efficiency (M
-1 
s
-1
) describes the ability of an enzyme to increase the 
reaction rate at low substrate concentrations. The maximum velocity (Vmax) occurs under 
saturating substrate concentrations (Wharton and Eisenthal, 1981; Palmer, 1995a).  
The catalytic parameters for both WTCSA-HIVPR and L38↑N↑L protease were determined 
by monitoring the cleavage of the chromogenic substrate Lys-Ala-Val-Nle-p-nitro-Phe-Glu-
Ala-Nle-NH2. The hydrolysis of HIV protease chromogenic substrate was monitored at 
300 nm. All experiments were carried out at 20 °C in 50 mM sodium acetate buffer (pH 5.0 
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buffer, with 0.1 M sodium chloride) with a final reaction volume of 120 μL. Experiments 
were carried out in triplicate and the data is reported as ± SD. For determination of KM, the 
protein concentration used was 200 nM. The substrate concentration was gradually increased 
until saturation had occurred. Determination of the kcat values, saturating substrate 
concentrations were used (for WTCSA-HIVPR saturation was obtained at 280 μM of 
substrate and 340 μM for L38↑N↑L protease). The enzyme concentration was varied (within 
range of 100 – 500 nM). The kcat/KM values were determined by using non-saturation 
substrate concentrations (10 – 50μM) and constant protein concentration of 200 nM.  
 
2.9.3. Inhibition studies 
The IC50 value is defined as the concentration of inhibitor that is required to inhibit the 
activity of an enzyme by 50%. The IC50 values were determined using three PIs (Saquinavir, 
Ritonavir and Nelfinavir) suspended in 3% (v/v) DMSO. The study was carried out for both 
WTCSA-HIVPR and L38↑N↑L protease. A reaction mixture consisted of 50 mM sodium 
acetate buffer (pH 5.0 buffer, with 0.1 M sodium chloride), 200 nM protein, 280 μM 
substrate concentration for WTCSA-HIVPR and 340 μM substrate concentration for 
L38↑N↑L protease and different concentrations of inhibitor (0.01 – 0.06 μM). The final 
reaction was 120 μL. Each reaction was carried out in triplicate. Saturating substrate 
concentrations were used to ensure that enzyme-substrate complexes are formed within the 
reaction mixture. As a control, all the above mentioned components without either WTCSA-
HIVPR or L38↑N↑L protease were used to make up the reaction mixture. 
 
2. 10 Homology modelling of L38↑N↑L protease 
Homology modelling is a method used to accurately ascertain the three dimension model of a 
target protein based on its amino acid sequence. The three dimensional structure of proteins is 
more conserved amongst evolutionarily related proteins as compared to their amino acids 
sequences (Kovalevsky et al., 2006). The target protein is required to at least 50% amino acid 
sequence similarity with an experimentally solved three dimensional structure (Marti-Renom 
et al., 2000; Tramontano et al., 2001; Schwede et al., 2003). Since a crystal structure of the 
L38↑N↑L protease was not determined, homology modelling was to predict its three 
dimensional structure. HHpred
TM
 (Soding et al., 2005) was used to model the L38↑N↑L 
protease structure. HHpred
TM
 is an online homology detection and structure prediction tool 
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(http://toolkit.tuebingen.mpg.de/hhpred). The three dimensional modelling was done using 
the crystal structure of HIV protease in complex with Darunavir (PDB id 2HS1, 0.84 Å and 
1.22 Å resolution, resolved by SER-CAT, Advanced Photon Source) (Kovalevsky et al., 
2006). The flow chart in Figure 10 shows the steps taken in the homology modelling. In order 
to validate the success of energy minimisation, refinement was perfomed on both L38↑N↑L 
protease and 2HS1. Ramachandran plots were generated by Molprobity
TM 
(Chen et al., 2010) 
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Figure 10 Flow chart showing the steps used for the prediction of the three dimensional 
structure of L38N↑L↑ mutant. 
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CHAPTER 3 
3. Results 
3.1. Verification of pET-HIVPRL38 sequence 
A Stratagene QuikChange® Lightning Site-Directed Mutagenesis Kit was used to generate 
the L38↑N↑L protease within the pET-HIVPRC plasmid DNA. Background mutations that 
accompanied amino acid insertions between point 38 and 39 are E35D, I36G, N37S, M46L, 
and D60E. The success of mutagenesis was confirmed by DNA sequencing at Inqaba 
Biotec®. The chromatograms in Figure 11 A show the positions of the generated mutations. 
Figure 11 B is a sequence alignment of WTCSA-HIVPR, sequence obtained from NICD and 
L38↑N↑L protease. 
 
3.2. Induction studies 
In order to optimise the over-expression of the L38↑N↑L protease, induction studies were 
carried out. This was done using varying IPTG concentrations (0 mM, 0.2 mM, 0.4 mM, 
0.6 mM, 0.8 mM, and 1 mM). Samples were collected at different time intervals; 0, 2, 4 and 6 
hours. Collected samples were resolved on a 16% Tricine gel in order to check for 
expression. Figure 12 shows a representative tricine gel of samples collected after four hours 
of induction. The gel shows seven lanes labelled A to G. Lanes A to F represent pellet 
samples with 0 mM, 0.2 mM, 0.4 mM, 0.6 mM, 0.8 mM and 1 mM IPTG, respectively. Lane 
G shows the molecular weight marker. Lanes A to F, indicate that HIV protease is expressed 
Although there was expression with different concentrations, 0.4 mM IPTG is the optimal 
IPTG concentration. WTCSA-HIVPR and the L38↑N↑L protease were expressed in E. coli 
BL21 (DE3) pLysS cells for 4 hours with 0.4 mM IPTG. 
 
3.3. Assessment of protein purity 
The protein was purified using DEAE anion exchange column. Purity of WTCSA-HIVPR 
and L38↑N↑L protease was assessed using Tricine SDS-PAGE as shown in Figure 13. Lane 
A is WTCSA-HIVPR protease, lane B is L38↑N↑L protease, and lane C is the molecular 
weight marker (Fermentas SM0661). A space between the protein samples and molecular   
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Figure 11 Verification of mutagenesis success 
A) Chromatogram showing regions in the pET-HIVPRL38 nucleotide sequence where the 
mutations were incorporated. Positions of E35D (GAA to GAT), I36G (ATC to GGT), 
N37S (AAT to AGC), inserts N (AAC) and L (CTG), M46L (ATG to CTG) as well as 
D60E (GAT to GAA) respectively. B) Multiple sequence alignment of WTCSA-HIVPR, 
sequence obtained from NICD and L38↑N↑L protease.  
A 
B 
WTCSA-HIVPR  
Seq from NICD 
L38↑N↑L mutant 
 
E35D 136G N37S               N        L                                                                            M46L                         D60E 
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WTCSA-HIVPR  
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Figure 12 Optimisation of L38↑N↑L protease  
Induction studies were performed on E. coli BL21 (DE3) pLysS cells transformed with pET-
HIVPRL38 plasmid. The gel above shows the samples after four hours of induction Lanes A 
to F represents samples resulting from different IPTG concentrations that were used (0, 0.2, 
0.4, 0.6, 0.8, 1mM). Lane G is the molecular weight marker. Lane C shows higher levels of 
over-expression relative to other Lanes. 
  
A          B       C          D        E          F         G    (kDa) 
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Figure 13 A) Tricine SDS-PAGE showing WTCSA-HIVPR and L38↑N↑L protease B) 
Calibration curve for WTCSA-HIVPR and the L38↑N↑L protease 
WTCSA-HIVPR protease is shown in Lane A, Lane B is L38↑N↑L protease and the 
molecular weight marker is shown in Lane C. Figure B is a calibration curve for 
determination of the molecular weights of WTCSA-HIVPR and L38↑N↑L protease. The 
arrow shows the position of the two proteases. The two proteases travelled 4.4 mm along the 
tricine gel and the approximate size of the proteins is 10 kDa. The correlation coefficient is 
0.95.
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weight marker was left to avoid cross contamination between the lanes. According to Figure 
13 A WTCSA-HIVPR protease appears to be pure, as no other bands visible. In lane B 
however, the band appears as a smear. This could be due to protease degradation products. 
Figure 13 B is the calibration curve used in the verification of protein size. According to the 
graph the size of both WTCSA-HIVPR and L38↑N↑L is 10 kDa. 
3.4. Secondary structural analysis 
Far-UV CD was used as a probe to determine the secondary structural integrity of WTCSA-
HIVPR and L38↑N↑L protease. Figure 14 is the CD spectra of WTCSA-HIVPR and 
L38↑N↑L protease. WTCSA-HIVPR CD spectrum is shown in red and L38↑N↑L in black. 
The spectra of both proteins start at the origin. WTCSA-HIVPR shows a trough at 216 nm 
and L38↑N↑L protease shows a trough at 203 nm. 
 
3.5. Tertiary structural characterization using fluorescence spectroscopy 
Fluorescence spectroscopy was used to establish the local environment surrounding the four 
tryptophan residues in HIV protease. Excitation at 280 nm results in excitation of tryptophan 
and tyrosine residues from both monomers (Trp 6, Trp 6ʹ, Trp 42, Trp 42ʹ, Tyr 59 and Tyr 
59ʹ), whereas excitation at 295 nm is the excitation of just the tryptophan residues. Figure 15 
A shows the fluorescence spectra of WTCSA-HIVPR and L38↑N↑L protease protein at 
280 nm excitation. There is no wavelength shift in the fluorescence spectra of WTCSA-
HIVPR and L38↑N↑L protease. An emission maximum is obtained at 349 nm for both 
proteins. However, the fluorescence intensity of L38↑N↑L is decreased. A similar pattern is 
observed with excitation at 295 nm, as shown in Figure 15 B. Emission maximum is also 
obtained at 349 nm and there is a decrease in fluorescence intensity of the L38↑N↑L protease.  
 
3.6. Determination of catalytic parameters 
The catalytic parameters for both WTCSA-HIVPR and L38↑N↑L were determined by 
monitoring the cleavage of the chromogenic substrate, Lys-Ala-Val-Nle-p-nitro-Phe-Glu-
Ala-Nle-NH2. 
Figure 16 shows the graphs from which the specific activity of WTCSA-HIVPR and 
L38↑N↑L protease were obtained. The specific activity was obtained from the slopes of these 
graphs. The specific activity value for WTCSA-HIVPR is higher than that obtained for  
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Figure 14 Far-UV CD spectra for WTCSA-HIVPR and L38↑N↑L protease  
The far-UV CD spectra for both WTCSA-HIVPR (―) and L38↑N↑L protease (―) show 
troughs at 215 nm and 203 nm respectively. 
  
44 
 
Wavelength (nm)
300 350 400 450 500
F
lu
o
re
sc
en
ce
 i
n
te
n
si
ty
 (
A
rb
it
ra
ry
 u
n
it
s)
0
200
400
600
800
 
 Wavelength (nm)
300 320 340 360 380 400 420 440 460
F
lu
o
re
sc
en
ce
 i
n
te
n
si
ty
 (
A
rb
it
ra
ry
 u
n
it
s)
0
50
100
150
200
250
300
350
 
 
 
 
Figure 15 Fluorescence spectra of WTCSA-HIVPR and L38↑N↑L protease  
Fluorescence spectra of both WTCSA-HIVPR (―) and L38↑N↑L protease (―) at (A) 280 
nm excitation with emission maximum at 349 nm and (B) 295 nm excitation with an 
emission maximum at 349 nm.  
A 
B 
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L38↑N↑L protease. These values are shown in Table 4. Figure 17 A and B are the graphs 
from which the KM of both WTCSA-HIVPR and L38↑N↑L protease were determined. Sigma 
plot® was used to fit the two curves, using the equation for a hyperbolic relationship. The KM 
and Vmax values were obtained for WTCSA-HIVPR. However, in the case of the L38↑N↑L 
protease, the data did not fit to graph described for a hyperbola. The experiments were 
performed several times using different protein concentrations and a similar pattern was 
obtained.  
The slopes of Figure 18 were used to determine the kcat values of WTCSA-HIVPR and 
L38↑N↑L protease. The kcat value of the WTCSA-HIVPR is much higher than of L38↑N↑L 
protease. Figure 19 shows the linear progress curves that were used to determine the kcat/ KM 
values. A final kcat/ KM value for WTCSA-HIVPR and L38↑N↑L protease was obtained by 
averaging values obtained from the slope of each graph. The kcat/ KM of WTCSA-HIVPR is 
three times higher than that of L38↑N↑L protease. These values are summerised in Table 4.  
Figure 20 shows the inhibition profiles for WTCSA-HIVPR and L38↑N↑L protease with 
Saquinavir, Ritonavir and Nelfinavir, respectively. Figure 20 A, B and C are the inhibition 
profile for WTCSA-HIVPR and L38↑N↑L protease with Saquinavir, Ritonavir. and 
Nelfinavir. Comparison between WTCSA-HIVPR and L38↑N↑L protease for each curve are 
not too different from each other. The IC50 values for WTCSA-HIVPR and L38↑N↑L 
protease with each PI are summarised in Table 5. 
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Figure 16: Specific activity of WTCSA-HIVPR and L38↑N↑L protease  
The specific activity of WTCSA-HIVPR (●) and L38↑N↑L protease (○) were determined by 
monitoring the hydrolysis of HIV protease chromogenic substrate at 300 nm. The specific 
activity was obtained from the slopes of the graphs. The correlation coefficients for the 
graphs are 0.95 and 0.96 for WTCSA-HIVPR and L38↑N↑L protease respectively. 
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Figure 17: Michaelis-Menten plot for determination of the KM values for A) WTCSA-
HIVPR and B) L38↑N↑L protease 
The WTCSA-HIVPR data fit to a graph described for a hyperbola, the L38↑N↑L protease 
data fit to a sigmoidal graph.   
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Figure 18 Determination of enzyme turn-over (kcat) 
The turn-over values for WTCSA-HIVPR (●) and L38↑N↑L protease (○) were determined 
from the slope of each graph. The correlation coefficient for the graph is 0.94 for WTCSA-
HIVPR and 0.96 for L38↑N↑L protease. 
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Figure 19 Determination of the catalytic efficiency (kcat/KM)  
The catalytic efficiencies were determined from the slopes of the graphs. Figure A, B and C 
show the kcat/KM values obtained using 100 nM, 200, and 300 nM of protein, respectively. 
This was done for WTCSA-HIVPR (●) and L38↑N↑L protease (○).The correlation 
coefficients for graphs in Figure A are 0.96 for WTCSA-HIVPR and 0.95 for L38↑N↑L 
protease. Figure B, 0.97 for both graphs and in Figure C the correlation coefficients for the 
graphs are 0.96 for WTCSA-HIVPR and 0.97 for L38↑N↑L protease.  
A 
B 
C 
C 
50 
 
Saquinavir concentration (M)
0.00 0.01 0.02 0.03 0.04 0.05 0.06
A
ct
iv
it
y
 p
er
ce
n
ta
g
e 
(%
)
0
20
40
60
80
100
Ritonavir concentration (M)
0.00 0.01 0.02 0.03 0.04 0.05 0.06
A
ct
iv
it
y
 p
er
ce
n
ta
g
e 
(%
)
0
20
40
60
80
100
Concentration of Nelfinavir (M)
0.00 0.01 0.02 0.03 0.04 0.05 0.06
A
ct
iv
it
y
 p
er
ce
n
ta
g
e 
(%
)
0
20
40
60
80
100
 
Figure 20 Determination of WTCSA-HIVPR and L38↑N↑L protease IC50 values 
The IC50 values were determined for A) Saquinavir, B) Ritonavir and C) Nelfinavir.  
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Table 4: Catalytic parameters for WTCSA-HIVPR and L38↑N↑L protease 
 
 Specific activity 
(μmol.min-1.mg-1) 
KM 
(μM) 
kcat 
(s
-1
) 
kcat/KM  
(μM-1.s-1) 
WTCSA-HIVPR C-SA 123.45 ± 6.4 226.43 ± 27.84 7.7   10-3 ± 5.0   10-4   5.6    10-5 ± 3.0   10-6 
L38↑N↑L  28.00 ± 1.3 - 1.0   10
-3
 ± 6.0   10-5 1.9   10-5 ± 9.7   10-7 
 
 
Table 5: IC50 values of WTCSA-HIVPR and L38↑N↑L with three protease inhibitors 
 
 
 IC50 Saquinavir (nM) IC50 Ritonavir (nM) IC50 Nelfinavir (nM) 
WTCSA-HIVPR C-SA 8 ± 3.6  11 ± 5.3  9 ± 6.4  
L38↑N↑L 8 ± 4.1  9 ± 5.4 10 ± 5.2 
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3.7. Homology modelling 
The protein data bank (Bernstein et al., 1977), has 588 protease structures. However HHpred 
picked one sequence that closely resembles the sequence of L38↑N↑L protease. HHpred 
selected 2HS1 (Kovalevsky et al., 2006) as the best template for L38↑N↑L protease. The 
sequence alignment is shown in Figure 21. The total energy before minimisation was - 3857 
kJ.mol
-1
 for L38↑N↑L protease and - 624.31 kJ.mol-1 for 2HS1. Table 6 below summarises 
the results obtained from MolProbity, before and after energy minimisation. This summary 
describes the percentage of residues with poor rotamers, Ramachandran outliers, and 
Ramachandran favoured conformations (Chen) The Ramachandran analyses show that 94% 
for L38↑N↑L protease and 97% for 2HS1 of non glycine and non-proline residues have 
conformational angles (φ and ψ) in the most favoured regions of the Ramachandran plot, 
Figure 22 and Figure 23 show the structural alignment of HIV proteases between subtype A 
(PDB id 3IXO) Robbins 2010), subtype B (PDB id 2HS1) (Kovalevsky , 2006), subtype C 
(PDB id 2R5Q) (Coman), South African subtype C protease (L38), subtype F (PDB id 2P3C) 
(Sanches 2007), and CRF_01 A/E (PDB id 2AQU) (Clemente, 2006). The Root Mean Square 
Deviation (RMSD) between L38↑N↑L protease and 2HS1 is 0.38 Å, with a structural 
alignment of 396 atoms. The RMSD between L38↑N↑L protease and 2R5Q subtype C 
protease is 0.87 Å, with 368 atoms. 
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L38↑N↑L.            PQITLWQRPLVSIKVGGQIKEALLDTGADDTVLEDGSLNLPGKWKPKLIGGIGGFIKVRQ 60 
2HS1.               PQITLWKRPLVTIKIGGQLKEALLDTGADDTIIEEMSL--PGRWKPKMIGGIGGFIKVRQ 58 
                    *******************************::*::**  *******:************ 
L38↑N↑L            YEQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF 101 
2HS1.              YDQIIIEIAGHKAIGTVLVGPTPVNIIGRNLLTQIGATLNF 99 
                   *:**:***:*:*******************:***:*:**** 
 
 
 
 
 
 
Figure 21 Sequence alignment of L38↑N↑L with 2HS1. 
The sequence identity between the two proteins is 81%. 
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Table 6 Summary of the results obtained from MolProbity
TM
 before and after energy 
minimisation in order to verify the stereochemistry of the model. 
 
 
Parameter  Expected 
value 
 L38N↑L↑ protease 
 
 2HS1 template 
Before
a
                After
a 
Before
a
        After
a 
Poor rotamers (%) < 1 2.38 1.39 4.94 3.08 
Ramachandran outliers (%) < 0.2 1.01 1.03 1.03 1.03 
Ramachandran favoured (%) > 98 94.95 93.81 96.91 96.91 
Cβ deviations > 0.25 Å 0 0 0 0 0 
Residues with bad bonds (%) 0 0 0 0 0 
Residues with bad angles (%) < 0.1  2.97 0 1.01 0 
 
a
 Energy minimization by GROMOS96 implemented on SPDBV v. 3.7 
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Figure 22 Ramachandran analyses of the homology modelling.  
A) L38↑N↑L protease and B) 2HS1 HIV protease by MolProbityTM. These Ramachnadram plots were derived after energy minimisation using GROMOS96. 
The regions with the cyan line indicate the most allowed region, and the region surrounded by the purple line shows the additionally allowed regions. The 
white background shows the disallowed regions.  
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Figure 23 Structural alignment of HIV protease subtypes. 
The structures of subtype A (cyan), subtype B (red) subtype C (green), South African subtype 
C (blue) subtype F (grey) and recombinant form CRF_01 A/E (yellow) were aligned. Most of 
the structures superimpose well, except for the flap hinge as shown in the model for 
L38↑N↑L protease.  
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CHAPTER 4 
4. Discussion 
 
HIV PIs were designed on the basis of the subtype B protease structure. How effective these 
drugs are on non B subtype proteases has been an area of debate. A few reports have 
suggested that genetic differences between subtypes have no effect on response to PIs (Frater 
et al., 2001; Frater et al., 2002). Other reports propose that it is the presence of certain 
polymorphisms in non B subtypes, particularly subtype B drug resistant mutations, that leads 
to inadequate response to PIs (Descamps et al., 1998; Abecasis et al., 2006). Based on this 
assumption, it was proposed that studies should be focused on subtype B drug resistant 
mutations, rather than non B subtype PI susceptibility (Kantor et al., 2005). However, studies 
conducted by the Freire group (Velazquez-Campoy et al., 2001c) suggest an increased 
catalytic efficiency and vitality for subtype C protease in the presence of inhibitors when 
compared to subtype B protease. In another study by the Freire group (Velazquez-Campoy et 
al., 2003b) there was evidence of decreased binding affinity in Subtype A, subtype C, South 
African subtype C and subtype G with PIs. This demonstrated that PIs were developed and 
optimised for subtype B proteases. In this study it was concluded that decrease in drug 
susceptibility, as a result of drug resistance mutations, is enhanced by the existence of 
naturally occurring polymorphisms in non B subtypes (Velazquez-Campoy et al., 2003b).  
A study done on subtype B proteases L33↑L and E35↑E showed that the insertions had led to 
an enlarged substrate binding pocket and local changes within the flap region. These changes 
caused insufficient inhibitor binding (Kozisek et al., 2008). In order to understand the effect 
of the L38↑N↑L insertions on South African subtype C protease a comparative structural and 
functional analysis between WTCSA-HIVPR and the L38↑N↑L protease was carried out.  
South African subtype C L38↑N↑L protease was isolated from a South African patient 
infected with HIV-1 subtype C. This patient was reportedly failing drug therapy. This is the 
first time such a polymorphism in has been reported or studied. The insertions are found in 
the flap hinge. With the emergence of L38↑N↑L protease, it was important to ask the 
following question: Has the HIV subtype C virus selected mutations that give rise to 
structural modifications leading to changes in function? Three important aspects will be 
assessed in order to answer this question. These aspects are; the structure and function of 
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L38↑N↑L protease, as well as suggestions from the homology model. The expectation is that 
if significant structural changes were to take place within the flap hinge, then, flap dynamics 
and therefore drug binding might be affected (Velazquez-Campoy et al., 2001b). 
Recombinant L38↑N↑L protease, together with its associated background mutations (E35D, 
I36G, N37S, M46L and D60E), was used in these studies. The L38↑N↑L protease was 
successfully purified, and the molecular weight verified (Figure 13 b). Specific activity 
assays were performed on the protein to ensure that it was catalytically active. This was 
important because the protease was recovered and refolded from inclusion bodies.  
The far-UV CD data shown in Figure 14 implies that the insertions have brought about 
structural alterations. The WTCSA-HIVPR far-UV CD spectrum shows a trough at 215 nm, 
as expected for proteins with a high β-sheet content (Adler et al., 1972). The far-UV CD 
spectrum of L38↑N↑L protease however, shows a trough at 203 nm. A trough in this region is 
found in the spectrum of proteins that are random coils (Greenfield, 1996). The CD spectrum 
of L38↑N↑L protease was obtained several times to ensure that the spectrum is representative 
of the mutant‟s secondary structure. However, the far-UV CD data is inconclusive because if 
L38↑N↑L protease was random coiled, it would not have been selected for by the virus, since 
the expectation is that there would be no catalytic activity. In addition, a crystal structure of 
HIV protease (unpublished data, PDB code 3U71) purified using the same protocol (as stated 
in section 2.5) was obtained. This structure contained all the three dimensional elements 
expected for HIV protease. CD studies were performed using protein in its apo form, i.e. 
unliganded form. Unliganded HIV protease is mainly in the semi-open conformation (Hornak 
et al., 2006a; Hornak et al., 2006b). A possible consequence could be L38↑N↑L protease has 
increased flexibility because of the additional amino acids in the flap hinge. Inhibitor binding 
has been shown to stabilise the dimeric structure of protease (Todd and Freire, 1999). It 
would therefore be useful to obtain far-UV CD studies, for acetylpepstatin – HIV protease 
complex in addition to the apo HIV protease. A study by L. Mpye 2010 for her MSc 
dissertation (Protein Structure-Function Research Unit, University of the Witwatersrand, 
Johannesburg, South Africa) was done on I36T↑T. In the study, the insertion caused no 
global structural changes, according to the far-UV CD data. The far-UV CD data for both 
wild type and I36TT mutant showed a trough at 216 nm, as expected for protein predominant 
in β-sheets (Mpye, 2010). This suggests that the structure of L38↑N↑L proteases is slightly 
different from I36T↑T. From the CD data, it may be concluded that the L38↑N↑L protease 
resulted with changes in the secondary structure of protease. The extent to which these 
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changes have occurred and the specific regions where these alterations are found is still not 
known. A crystal structure of L38↑N↑L protease would be useful. The structure of the 
L38↑N↑L protease was further analysed using fluorescence. The information provided by the 
fluorescence data indicates the changes that have taken place within the vicinity of the 
tryptophan residues.  
The fluorescence data does not suggest any significant changes in the local environment of 
the four tryptophan residues of protease. According to Figure 15 the emission maximum for 
WTCSA-HIVPR and L38↑N↑L is 349 nm for both, however, there is a decrease in the 
fluorescence intensity of L38↑N↑L protease. Differences in the fluorescence intensity 
between WTCSA-HIVPR and L38↑N↑L protease may possibly be an effect of fluorescence 
quenching caused by nearby charged amino acids (Lakowicz, 2006). A possible reason for 
the lack of a wavelength shift in L38↑N↑L protease could be that the local environment of the 
tryptophan residues is still the same. However, this does not imply that the orientation of the 
tryptophan residues did not change. The decrease in fluorescence intensity may be due to 
fluorescence quenching of tryptophan. Tryptophan can be quenched by charged, 
neighbouring amino acid residues (Lakowicz, 2006). The insertions are located in the flap 
hinge of the mutant; this is within the vicinity of tryptophan 42. Within a 7 Å sphere of Trp 
42 there are five basic residues Lys 41, Lys 43, Lys 45, Lys 55 and Arg 57; three 
hydrophobic residues, Leu 38, Val 56 and Tyr 59; and four conformationally important 
residues; Pro 39, Pro44, Gly 40 and Pro 39. There is a polar uncharged group, Gln 58 and a 
negatively charged residue, Asp 60. Amongst these amino acid residues, those that can act as 
potential quenchers are: the amide group of glutamine 58, the carboxyl group of aspartic acid 
60, the Ɛ-amino group of the lysine residues and the phenol group in tyrosine 59. Quenching 
by the α-amino group of glutamine, asparagine and lysine also contributes to quenching 
(Chen and Barkley, 1998). Fluorescence quenching is affected by proximity, specific 
geometry or local polarity (Chen and Barkley, 1998; Ullrich et al., 2000). Based on this 
information it can be inferred that in L38↑N↑L protease, there is greater interaction between 
Trp 42 and the quenching amino acids, possibly due to an extended flap, as compared to the 
WTCSA-HIVPR. According to the structural information from far-UV CD and fluorescence, 
it can be assumed that the insertions in L38↑N↑L protease have caused structural changes that 
require further analysis. 
The protease flaps are important during substrate binding. Apart from the obvious role of 
opening and closing, they also form important interactions: A crystal structure analysis of 
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HIV protease complexed with acetylpepstatin showed that the inhibitor forms hydrogen 
bonds with main chain residues in the flap and residues in the active site loops (Fitzgerald et 
al., 1990). The flap hinge and core regions play an important role in flap dynamics (Rose et 
al., 1998; Todd and Freire, 1999; Scott and Schiffer, 2000). Comparison of liganded and 
unliganded protease crystal structures shows that considerable structural alterations take place 
as a result of substrate binding. Upon substrate binding, the only regions that remain 
unchanged are the dimer interface and residues of the active site (Fitzgerald et al., 1990). 
This could be a consequence of substrate recognition. It is proposed that substrate recognition 
in HIV protease is based on structure rather than sequence. The two protease monomers 
undergo structural alterations in order to accommodate asymmetrical substrates (Prabu-
Jeyabalan et al., 2000; Prabu-Jeyabalan et al., 2002).  
Sodium acetate buffer pH 5, which was used in the enzymatic assays, is not present under 
physiological conditions. However, this buffer mimics the environment which HIV protease 
processes Gag and Gag-Pol polyproteins within the cell. Proteolysis during viral maturation 
occurs near the plasma membrane (Henderson et al., 1983; Mervis et al., 1988), which is an 
acidic pH environment (Honig et al., 1986). The catalytic activity of WTCSA-HIVPR and 
L38↑N↑L protease were determined using a substrate that mimics a Gag-Pol polyprotein 
cleavage site. The L38↑N↑L protease has a lower specific activity value compared to the 
WTCSA-HIVPR, as shown in Table 4. The enzyme turn-over number can be affected by 
substrate binding. If binding is too loose, the required interactions do not take place, and there 
is a large energy barrier towards the transition-state. If binding is too tight, the intermediate 
becomes too stable for product to be released (Albery and Knowles, 1976). The turn-over 
value for L38↑N↑L is seven times less than that of the WTCSA-HIVPR (Table 4). This 
suggests that substrate binding may be too loose. If the turn-over number is low, it makes 
sense why the specific activity is lower in L38↑N↑L protease. The KM value obtained for 
WTCSA-HIVPR was 226.43 ± 27.84 μM, as seen in Table 4. The KM value for L38↑N↑L 
protease, on the other hand, could not be obtained. The data, as shown in Figure17, does not 
fit a hyperbolic Michaelis-Menten graph (Michaelis et al., 2011), instead it has a sigmoidal 
shape. A sigmoidal shape for velocity versus substrate graph is often associated with 
allosteric enzymes. However, HIV protease has one active site (McKeever et al., 1989; Navia 
et al., 1989; Wlodawer et al., 1989).  
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The IC50 is the inhibitor concentration that reduces the activity by 50% (Burlingham and 
Widlanski, 2003). According to Table 5 the IC50 values for WTCSA-HIVPR and L38↑N↑L 
protease were not significantly different from each other. This suggests that the L38↑N↑L 
protease insertions do not affect inhibitor binding. In a previous study, IC50 values were 
obtained for wild type protease with saquinavir (7.6 nM), nelfinavir (17.3 nM) and ritonavir 
(19.1 nM) (Lerato Mpye, 2010). The IC50 value of 7.6 nM obtained for saquinavir is 
comparable to the values obtained for both wild type and L38↑N↑L protease as shown in 
Table 5. The values obtained for nelfinavir and ritonavir are notably different, however, this 
data is not sufficient enough to draw conclusions with regards to the behaviour of L38↑N↑L 
protease with the above mentioned PIs. This is because IC50 is considered a relative value and 
is highly reliant on the concentration of substrate used in the assays. Therefore determination 
of IC50 values should be used along with the inhibition constant Ki so that a complete analysis 
of the behaviour of HIV protease is with inhibitors (Burlingham and Widlanski, 2003).  
It should be emphasised that the kinetic studies are not a reflection of what is taking place in 
vivo. When evading drug pressure, HIV selects mutations within the Gag-Pol cleavage sites, 
along with mutations within the protease. This way it is able to maintain function even in the 
presence of PIs (Doyon et al., 1996; Zhang et al., 1997; Mammano et al., 1998). Based on 
this, it is possible that the substrate used in these studies does not contain the cleavage site 
mutations that may have been selected for by the virus for cleavage by the L38↑N↑L 
protease. This could explain why the specific activity of L38↑N↑L protease is so low. 
A crystal structure of L38↑N↑L with bound inhibitor could possibly provide an understanding 
of the interactions involved in this mutant. However, due to time constraints, a crystal 
structure of L38↑N↑L protease could not be obtained. Homology modelling was used to 
predict the structure of L38↑N↑L protease. Although this method is important in helping 
explain the changes that have taken place in the flap region, it is theoretical, and does not 
override obtaining a crystal structure of L38↑N↑L protease. An online modelling software, 
HHpred
TM
 was used. In order to avoid any bias, the modeller was allowed to choose 
structures, from the Protein Data Bank (PDB) that are most likely to resemble L38↑N↑L 
protease. There are about 588 structures associated with HIV protease in the PDB (Bernstein 
et al., 1977). Out of this array of structures, the modeller chose HIV protease 2HS1 
(Kovalevsky et al., 2006). This is a subtype B protease in complex with Darunavir. This was 
against expectation because it did not select the subtype C proteases such as 2R5Q (subtype 
C protease in complex with nelfinavir), or the 2R8N, the apo enzymes (subtype C protease) 
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(Coman et al., 2008a). The L38↑N↑L protease has 81% sequence identity with 2HS1. This is 
much lower than with 2R5Q, which gave a sequence identity of 90%, and WTCSA-HIVPR, 
93%. 
The refinement of the model using GROMOS96 appeared to be successful on the basis of the 
improvement of the stereochemical parameters done with the MolProbity
TM
 algorithm. The 
2HS1 template was used as a positive control to ensure the success of the refinement. As 
shown in Table 6, the percentage of poor rotamers decreased by approximately 1% after 
energy minimisation. In addition, after energy minimisation, the number of rotamers with bad 
angles was zero. The percentage of Ramachandran outliers and favoured remained the same. 
For the model, there was an approximate 1% decrease in the percentage of poor rotamers. 
There was also a decrease in the percentage of residues with poor angles after energy 
minimisation. The stereochemistry analysis was important in validating the structure of the 
model. The flap hinge of the L38↑N↑L protease falls within the allowed regions of the 
Ramachndran plot. This validates the structure of the model. The structural alignment in 
Figure 23 shows that the global structure of HIV protease is conserved amongst the subtypes. 
The differences lie in the flap hinge of L38↑N↑L protease and the template 2HS1. 2HS1 has 
ninety-nine amino acids, and L38↑N↑L protease has 101. If 2HS1 has the same fold as 
L38↑N↑L protease in the flap hinge, it suggests that the insertions in L38↑N↑L protease are 
not the cause of this fold in L38↑N↑L protease. The hinge region folding as seen in L38↑N↑L 
protease could be a polymorphism induced by the background mutations found in L38↑N↑L 
protease. 
Inferences from the 2HS1 M46L crystal structure can be used to explain the structure of 
L38↑N↑L protease because the same mutation is found in the L38↑N↑L protease. The M46L 
mutation is selected in seven PIs and is a major Indinavir drug resistant mutation (Johnson et 
al., 2005). The M46L mutation is found in the flap region and has no direct contact with 
bound inhibitor. However, Met46 forms hydrogen bonds with substrate analogues (Tie et al., 
2005). It is therefore assumed that this mutation affects inhibitor binding by reducing 
hydrophobic interactions or by actually increasing its interaction with the substrate 
(Kovalevsky et al., 2006). The M46L mutation within L38↑N↑L protease could be behaving 
in a similar way. However, the effect of polymorphisms cannot be studied in isolation, the 
background mutations that exist alongside it, have to be taken into account (Velazquez-
Campoy et al., 2003b). 
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Further analysis of the 2HS1 M46L crystal structure reveals that this protease has an 
allosteric site, as shown in Figure 24. The second binding site is found on one side of the flap 
surface. Apparently, the Darunavir binds the active site and flap surface with different 
configurations (Kovalevsky et al., 2006). Although the structure of L38↑N↑L protease  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24 Ribbon representation of HIV protease showing the second inhibitor binding 
site 
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The two Darunavir molecular are shown in pink. The second Darunavir binds in a cleft on the 
surface of one of the flaps. This figure was generated using PyMOL (PDB code 2HS1) 
(DeLano, 2006). 
 
obtained from the model is theoretical, it re-emphasises the possibility of L38↑N↑L protease 
having an allosteric site, as this related to the data for KM determination. The binding of the 
second inhibitor on the surface induces a conformational change in the protease (Kovalevsky 
et al., 2006). If L38↑N↑L protease does have a second binding site this could have major 
implications on drug binding. In the 2HS1 study however, there was no mention on how the 
KM was obtained and what shape the graph had. This could have helped confirm the shape of 
the curve obtained for L38↑N↑L protease.  
Conclusion 
To answer the question previously stated HIV subtype C virus has indeed selected mutations 
that gave rise to local structural modifications leading to changes in function. The extent of 
these structural modifications is not known. The homology model of L38↑N↑L protease 
shows a flap hinge that is slightly altered. In addition, it suggests there is a second inhibitor 
binding site. A crystal structure of L38↑N↑L protease would therefore be useful for 
understanding this unique protease with 101 amino acids. 
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